Collectively, these findings across four independent pancreatic tumor models validate the robust and reproducible antitumor activity of combined GIPC-1 knockdown and GEM therapy, highlighting the synergistic potential of this strategy to overcome the limited efficacy of monotherapies. Here, GIPC1 is linked to pancreatic neoplasm.